Novo Seeks US, EU Approval for Etavopivat in Sickle Cell Disease
If approved, Novo’s etavopivat could offer a new disease-modifying treatment approach for people living with sickle cell disease.
E-MAIL: support@healthxploreindia.com
E-MAIL: healthxploreindia@gmail.com
If approved, Novo’s etavopivat could offer a new disease-modifying treatment approach for people living with sickle cell disease.
CeleCor’s Zalunfiban is a subcutaneously injected inhibitor of the platelet glycoprotein (GP) IIb/IIIa receptor designed for rapid pre-hospital treatment of STEMI heart attacks.
Following confirmation of the PDUFA target action date of April 30, 2027, Kowa anticipates a US commercial launch of the K-911 glaucoma eye drop in the second half of 2027, subject to FDA approval.
HealthXplore is a digital platform dedicated to delivering insights into what’s new and what’s next in healthcare, pharmaceuticals, and medical innovation. We aim to bridge the gap between complex industry developments and informed audiences by presenting credible, timely, and engaging content.
Contact: +91 9354115542
HealthXploreIndia @2026. All Rights Reserved.


